EP2049536A2 - Inhibiteurs viraux polycycliques - Google Patents

Inhibiteurs viraux polycycliques

Info

Publication number
EP2049536A2
EP2049536A2 EP07799720A EP07799720A EP2049536A2 EP 2049536 A2 EP2049536 A2 EP 2049536A2 EP 07799720 A EP07799720 A EP 07799720A EP 07799720 A EP07799720 A EP 07799720A EP 2049536 A2 EP2049536 A2 EP 2049536A2
Authority
EP
European Patent Office
Prior art keywords
substituted
alkyl
heterocyclic
group
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07799720A
Other languages
German (de)
English (en)
Inventor
Ronald Conrad Griffith
Christopher Don Roberts
Franz Ulrich Schmitz
Janos Botyanszki
Rachel Elizabeth Marek
Dong-Fang Shi
Son Minh Pham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
Genelabs Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Technologies Inc filed Critical Genelabs Technologies Inc
Publication of EP2049536A2 publication Critical patent/EP2049536A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention relates to the field of pharmaceutical chemistry, in particular to compounds, compositions and methods for treating viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses.
  • Chronic infection with ⁇ CV is a major health problem associated with liver cirrhosis, hepatocellular carcinoma and liver failure.
  • An estimated 170 million chronic carriers worldwide are at risk of developing liver disease. ' In the United States alone 2.7 million are chronically infected with HCV, and the number of HCV -related deaths in 2000 was estimated between 8,000 and 10,000, a number that is expected to increase significantly over the next years.
  • Infection by HCV is insidious in a high proportion of chronically infected (and infectious) carriers who may not experience clinical symptoms for many years.
  • Liver cirrhosis can ultimately lead to liver failure.
  • Liver failure resulting from chronic HCV infection is now recognized as a leading cause of liver transplantation.
  • HCV is a member of the Flaviviridae family of RNA viruses that affect animals and humans.
  • the genome is a single ⁇ 9.6-kilobase strand of RNA, and consists of one open reading frame that encodes for a polyprotein of -3000 amino acids flanked by untranslated regions at both 5' and 3' ends (5'- and 3'-UTR).
  • the polyprotein serves as the precursor to at least 10 separate viral proteins critical for replication and assembly of progeny viral particles.
  • the organization of structural and non-structural proteins in the HCV polyprotein is as follows: C-El-E2-p7-NS2-NS3-NS4a-NS4b-NS5a-NS5b.
  • HCV infection can theoretically be cured. While the pathology of HCV infection affects mainly the liver, the virus is found in other cell types in the body including peripheral blood lymphocytes. 3 ' 4
  • IFN-alpha interferon alpha
  • IFN-alpha belongs to a family of naturally occurring small proteins with characteristic biological effects such as antiviral, immunoregulatory and antitumoral activities that are produced and secreted by most animal nucleated cells in response to several diseases, in particular viral infections.
  • IFN-alpha is an important regulator of growth and differentiation affecting cellular communication and immunological control.
  • Treatment of HCV with interferon has frequently been associated with adverse side effects such as fatigue, fever, chills, headache, myalgias, arthralgias, mild alopecia, psychiatric effects and associated disorders, autoimmune phenomena and associated disorders and thyroid dysfunction.
  • Ribavirin an inhibitor of inosine 5 '-monophosphate dehydrogenase (IMPDH)
  • IMPDH inosine 5 '-monophosphate dehydrogenase
  • a number of approaches are being pursued to combat the virus. They include, for example, application of antisense oligonucleotides or ribozymes for inhibiting HCV replication. Furthermore, low-molecular weight compounds that directly inhibit HCV proteins and interfere with viral replication are considered as attractive strategies to control HCV infection.
  • the viral targets the NS3/4a protease/helicase and the NS5b RNA- dependent RNA polymerase are considered the most promising viral targets for new drugs. 6"
  • antiviral activity can also be achieved by targeting host cell proteins that are necessary for viral replication.
  • Watashi et al 9 show how antiviral activity can be achieved by inhibiting host cell cyclophilins.
  • a potent TLR7 agonist has been shown to reduce HCV plasma levels in humans. 10
  • none of the compounds described above have progressed beyond clinical trials. 6 ' 8
  • the present invention is directed to novel compounds, compositions, and methods for treating of viral infections in mammals mediated, at least in part, by a member of the Flaviviridae family viruses such as HCV.
  • a member of the Flaviviridae family viruses such as HCV.
  • T is C 1 to Cs alkylene wherein one or two -CH 2 - groups are optionally replaced with -NR 0 -, -S-, or -O- and optionally two -CH 2 - groups together form a double bond provided that T does not contain an -O-O-, -S-O-, or -S-S- group;
  • R a is independently selected from the group consisting of hydrogen, alkyl, and substituted alkyl
  • R and R are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or, alternatively, R 2 and R 2 as defined are taken together with the carbon atom pendent thereto to form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group,
  • one of R or R is hydrogen, alkyl or substituted alkyl, and the other is joined, together with the carbon atom pendent thereto, with either the R and the oxygen atom pendent thereto or R and the nitrogen atom pendent thereto to form a heterocyclic or substituted heterocyclic group;
  • R is selected from hydrogen and alkyl or, when R and R are not taken together to form a ring and when R 2 or R 2 and R 7 or R 8 are not joined to form a heterocyclic or substituted heterocyclic group, then R 3 , together with the nitrogen atom pendent thereto, may be taken together with one of R 2 and R 2 to form a heterocyclic or substituted heterocyclic ring group; (e) -C(X 2 )-N(R 3 )CR 25 R 26 R 27 , wherein X 2 and R 3 are defined above, and R 25 , R 26 and R 27 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R 25 and R 26 together with the carbon atom pendent thereto form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; and
  • Y is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, halo, hydroxy, nitro, aryl, heteroaryl, substituted aryl, and substituted heteroaryl;
  • J and K are independently selected from the group consisting of N, NH, CX, and N- oxide provided that J and K are not both CX;
  • W 1 , W 2 , W 3 , W 4 , W 5 , and W 6 are independently selected from the group consisting of N, N-oxide, or CX, provided that no more than one of J, K, and W 1 -W 6 is an N-oxide and provided that one of W 4 or W 5 is C-Y; each X is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, halo, hydroxy, and nitro;
  • T is C 1 to C 5 alkylene wherein one or two -CH 2 - groups are optionally replaced with -NR 0 -, -S-, or -O- and optionally two -CH 2 - groups together form a double bond provided that T does not contain an -O-O-, -S-O-, or -S-S- group;
  • R a and R c are independently selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
  • n is 0, 1, or 2;
  • R 2 and R 2 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or, alternatively, R and R as defined are taken together with the carbon atom pendent thereto to form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group, or, still further alternatively, one of R 2 or R 2 is hydrogen, alkyl or substituted alkyl, and the other is joined, together with the carbon atom pendent thereto, with either the R 7 and the oxygen atom pendent thereto or R 8 and the nitrogen atom pendent thereto to form a heterocyclic or substituted heterocyclic group;
  • R is selected from hydrogen and alkyl or, when R and R are not taken together to form a ring and when R or R and R or R are not joined to form a heterocyclic or substituted heterocyclic group, then R 3 , together with the nitrogen atom pendent thereto, may be taken together with one of R 2 and R 2 to form a heterocyclic or substituted heterocyclic ring group;
  • R 25 , R 26 and R 27 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R and R together with the carbon atom pendent thereto form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; and
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound, tautomer, or stereoisomer of Formula (A).
  • a method for treating a viral infection in a mammal mediated at least in part by a virus in the Flaviviridae family of viruses comprising administering to said mammal a composition of Formula (A).
  • the viral infection is mediated by hepatitis C virus.
  • alkyl refers to monovalent alkyl groups having from 1 to 10 carbon atoms, preferably from 1 to 5 carbon atoms and more preferably 1 to 3 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, ⁇ o-propyl, n- butyl, t-butyl, n-pentyl and the like.
  • Substituted alkyl refers to an alkyl group having from 1 to 3, and preferably 1 to 2, substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
  • Alkylene refers to divalent straight chain alkyl groups having from 1 to 5 carbons.
  • Alkoxy refers to the group “alkyl-O-" which includes, by way of example, methoxy, ethoxy, n-propoxy, ⁇ o-propoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy and the like.
  • Substituted alkoxy refers to the group “substituted alkyl-O-”.
  • Acyl refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl- C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)- cycloalkyl- C(O)-, substituted cycloalkyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O), heterocyclic-C(O)-, and substituted heterocyclic-C(O)-.
  • Acylamino refers to the group -C(O)NR f R g where R f and R g are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R f and R g are joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring.
  • Acyloxy refers to the groups alkyl-C(O)O-, substituted alkyl-C(O)O-, alkenyl- C(O)O-, substituted alkenyl-C(O)O-, alkynyl-C(O)O-, substituted alkynyl-C(O)O-, aryl- C(O)O-, substituted aryl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, heteroaryl-C(O)O-, substituted heteroaryl-C(O)O-, heterocyclic-C(O)O-, and substituted heterocyclic-C(O)O-.
  • Alkenyl refers to alkenyl group having from 2 to 10 carbon atoms, preferably having from 2 to 6 carbon atoms, and more preferably 2 to 4 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation.
  • Substituted alkenyl refers to alkenyl groups having from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic provided that any hydroxyl substitution is not pendent to a vinyl carbon atom.
  • Alkynyl refers to alkynyl group having from 2 to 10 carbon atoms, preferably having from 2 to 6 carbon atoms, and more preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1-2 sites of alkynyl unsaturation.
  • Substituted alkynyl refers to alkynyl groups having from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic provided that any hydroxyl substitution is not pendent to an acetylenic carbon atom.
  • Amino refers to the group -NH 2 .
  • Substituted amino refers to the group -NR 11 R 1 where R h and R 1 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R h and R 1 are joined, together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group provided that R h and R 1 are both not hydrogen.
  • R h is hydrogen and R 1 is alkyl
  • the substituted amino group is sometimes referred to herein as alkylamino.
  • R h and R 1 are alkyl
  • the substituted amino group is sometimes referred to herein as dialkylamino.
  • Aminoacyl refers to the groups -NR J C(O)alkyl, -NR J C(O)substituted alkyl, -NR J C(O)-cycloalkyl, -NR J C(O)substituted cycloalkyl, -NR J C(O)alkenyl, -NR J C(O)substituted alkenyl, -NR J C(O)alkynyl, -NR J C(O)substituted alkynyl, -NR J C(O)aryl, -NR J C(O)substituted aryl, -NR J C(O)heteroaryl, -NR J C(O)substituted heteroaryl, -NR J C(O)heterocyclic, and -NR J C(O)substituted heterocyclic where R J is hydrogen or alkyl.
  • Aryl or “Ar” refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H- 1 ,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the point of attachment is to an aromatic ring atom.
  • Preferred aryls include phenyl and naphthyl.
  • Alkyl or “arylalkyl” refers to the group aryl-alkyl- and includes, for example, benzyl.
  • Substituted aryl refers to aryl groups which are substituted with from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of hydroxy, acyl, acylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, carboxy, carboxy ester, cyano, thiol, cycloalkyl, substituted cycloalkyl, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, and substituted heterocyclyloxy.
  • Arylene and “substituted arylene” refer to divalent aryl and substituted aryl groups as defined above.
  • Phenylene is a 6-membered optionally substituted arylene group and includes, for example, 1 ,2-phenylene, 1,3 -phenylene, and 1,4-phenylene.
  • Aryloxy refers to the group aryl-O- that includes, by way of example, phenoxy, naphthoxy, and the like.
  • Substituted aryloxy refers to substituted aryl-O- groups.
  • Carboxy ester refers to the groups -C(O)O-alkyl, -C(O)O-substituted alkyl, -C(O)O-alkenyl, -C(O)O-substituted alkenyl, -C(O)O-alkynyl, -C(O)O-substituted alkynyl, -C(O)O-aryl, -C(O)O-substituted aryl, -C(O)O-heteroaryl, -C(O)O-substituted heteroaryl, -C(O)O-heterocyclic, and -C(O)O-substituted heterocyclic.
  • Preferred carboxy ester are -C(O)O-alkyl, -C(O)O-substituted alkyl, -C(O)O-aryl, and -C(O)O-substituted aryl.
  • Cycloalkyl refers to cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings optionally comprising 1 to 3 exo carbonyl or thiocarbonyl groups.
  • Suitable cycloalkyl groups include, by way of example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, 3-oxocyclohexyl, and the like.
  • one or more of the rings may be other than cycloalkyl (e.g., aryl, heteroaryl or heterocyclic) provided that the point of attachment is to a carbon ring atom of the cycloalkyl group.
  • the cycloalkyl group does not comprise 1 to 3 exo carbonyl or thiocarbonyl groups.
  • the cycloalkyl group does comprise 1 to 3 exo carbonyl or thiocarbonyl groups. It is understood, that the term "exo" refers to the attachment of a carbonyl or thiocarbonyl to a carbon ring atom of the cycloalkyl group.
  • Substituted cycloalkyl refers to a cycloalkyl group, having from 1 to 5 substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
  • Cycloalkenyl refers to cyclic alkenyl but not aromatic groups of from 5 to 10 carbon atoms having single or multiple cyclic rings optionally comprising 1 to 3 exo carbonyl or thiocarbonyl groups.
  • Suitable cycloalkenyl groups include, by way of example, cyclopentyl, cyclohexenyl, cyclooctenyl, 3-oxocyclohexenyl, and the like.
  • one or more of the rings may be other than cycloalkenyl (e.g., aryl, heteroaryl or heterocyclic) provided that the point of attachment is to a carbon ring atom of the cycloalkyl group.
  • the cycloalkenyl group does not comprise 1 to 3 exo carbonyl or thiocarbonyl groups. In another embodiment, the cycloalkenyl group does comprise 1 to 3 exo carbonyl or thiocarbonyl groups. It is understood, that the term “exo” refers to the attachment of a carbonyl or thiocarbonyl to a carbon ring atom of the cycloalkenyl group.
  • Substituted cycloalkenyl refers to cycloalkenyl groups having from 1 to 5 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic provided that for hydroxyl substituents the point of attachment is not to a vinyl carbon atom.
  • Cycloalkoxy refers to -O-cycloalkyl groups.
  • Substituted cycloalkoxy refers to -O-substituted cycloalkyl groups.
  • Halo or halogen refers to fluoro, chloro, bromo and iodo and preferably is fluoro or chloro.
  • Haloalkyl refers to an alkyl group substituted with 1 to 5 halogen groups.
  • An example of haloalkyl is CF 3 .
  • Heteroaryl refers to an aromatic group of from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, within the ring.
  • such heteroaryl groups are aromatic groups of from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur within the ring.
  • Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl).
  • the sulfur atom(s) in the heteroaryl group may optionally be oxidized to sulfoxide and sulfone moieties.
  • Substituted heteroaryl refers to heteroaryl groups that are substituted with from 1 to 3 substituents selected from the same group of substituents defined for substituted aryl.
  • substituents selected from the same group of substituents defined for substituted aryl.
  • Heteroarylene and “substituted heteroarylene” refer to divalent heteroaryl and substituted heteroaryl groups as defined above.
  • Heteroaryloxy refers to the group -O-heteroaryl and "substituted heteroaryloxy” refers to the group -O-substituted heteroaryl.
  • Heterocycle or “heterocyclic” or “heterocyclyl” refers to a saturated or unsaturated but not aromatic group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur or oxygen within the ring which ring may optionally comprise 1 to 3 exo carbonyl or thiocarbonyl groups.
  • such heterocyclic groups are saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur, or oxygen within the ring.
  • the sulfur atom(s) in the heteroaryl group may optionally be oxidized to sulfoxide and sulfone moieties.
  • one or more of the rings may be other than heterocyclic
  • the heterocyclic group does not comprise 1 to 3 exo carbonyl or thiocarbonyl groups. In a preferred embodiment, the heterocyclic group does comprise 1 to 3 exo carbonyl or thiocarbonyl groups. It is understood, that the term "exo" refers to the attachment of a carbonyl or thiocarbonyl to a carbon ring atom of the heterocyclic group.
  • Substituted heterocyclic refers to heterocycle groups that are substituted with from 1 to 3 of the same substituents as defined for substituted cycloalkyl.
  • Preferred substituents for substituted heterocyclic groups include heterocyclic groups having from 1 to 5 having substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
  • heterocyclic When a specific heterocyclic is defined as "substituted”, e.g., substituted morpholino, it is understood that such a heterocycle contains the 1 to 3 substituents as recited above.
  • heterocycles and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydro-isoquinoline, 4,5,6,7-te
  • Heterocyclyloxy refers to the group -O-heterocyclic and "substituted heterocyclyloxy” refers to the group -O-substituted heterocyclic.
  • thiol refers to the group -SH.
  • Isosteres are different compounds that have different molecular formulae but exhibit the same or similar properties.
  • tetrazole is an isostere of carboxylic acid -COOH because it mimics the properties of carboxylic acid even though they both have very different molecular formulae. Tetrazole is one of many possible isosteric replacements for carboxylic acid.
  • carboxylic acid isosteres of the present invention include -SO3H, -SO 2 HNR k , -PO 2 (R k ) 2 , -CN, -PO 3 (R k ) 2 , -OR k , -SR k , -NHC0R k , -N(R k ) 2 , -CON(R k ) 2 , -C0NH(0)R k , -CONHNHSO 2 R k , -COHNSO 2 R k , and -CONR k CN, where R k is selected from hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, thio, thioalkyl, alkylthio, substituted sul
  • carboxylic acid isosteres can include 5-7 membered carbocycles or heterocycles containing any combination of CH 2 , O, S, or N in any chemically stable oxidation state, where any of the atoms of said ring structure are optionally substituted in one or more positions.
  • the following structures are non- limiting examples of preferred isosteres contemplated by this invention:
  • the atoms of said ring structure may be optionally substituted at one or more positions with R k .
  • the present invention contemplates that when chemical substituents are added to a carboxylic isostere then the inventive compound retains the properties of a carboxylic isostere.
  • the present invention contemplates that when a carboxylic isostere is optionally substituted with one or more moieties selected from R k , then the substitution cannot eliminate the carboxylic acid isosteric properties of the inventive compound.
  • the present invention contemplates that the placement of one or more R k substituents upon the carboxylic acid isostere shall not be permitted at one or more atom(s) which maintain(s) or is/are integral to the carboxylic acid isosteric properties of the inventive compound, if such substituent(s) would destroy the carboxylic acid isosteric properties of the inventive compound.
  • "Carboxylic acid bioisosteres” are compounds that behave as isosteres of carboxylic acids under biological conditions.
  • Metal refers to any derivative produced in a subject after administration of a parent compound.
  • the metabolite may be produced from the parent compound by various biochemical transformations in the subject such as, for example, oxidation, reduction, hydrolysis, or conjugation.
  • Metabolites include, for example, oxides and demethylated derivatives.
  • “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • Prodrug refers to art recognized modifications to one or more functional groups which functional groups are metabolized in vivo to provide a compound of this invention or an active metabolite thereof.
  • Such functional groups are well known in the art including acyl groups for hydroxyl and/or amino substitution, esters of mono-, di- and tri-phosphates wherein one or more of the pendent hydroxyl groups have been converted to an alkoxy, a substituted alkoxy, an aryloxy or a substituted aryloxy group, and the like.
  • Treating” or “treatment” of a disease in a refers to 1) preventing the disease from occurring in a patient that is predisposed or does not yet display symptoms of the disease; 2) inhibiting the disease or arresting its development; or 3) ameliorating or causing regression of the disease.
  • Patient refers to mammals and includes humans and non-human mammals.
  • arylalkyloxycarbonyl refers to the group (aryl)-(alkyl)-O-C(O)-; the term “alkylaryloxy” refers to the group alkyl-aryl-O-; the term “arylalkyloxy” refers to the group aryl-alkyl-O-, “thioalkyl” refers to HS-alkyl-; “alkylthio” refers to alkyl-S- etc..
  • substituents may also have alternate but equivalent names. For example, the term 2-oxo-ethyl and the term carbonylmethyl both refer to the -C(O)CH 2 - group.
  • impermissible substitution patterns e.g., methyl substituted with 5 fluoro groups or a hydroxy group alpha to ethenylic or acetylenic unsaturation.
  • impermissible substitution patterns are well known to the skilled artisan.
  • ring H and ring I are independently an optionally substituted 6 member aryl or an optionally substituted 5 or 6 member heteroaryl having one, two, or three ring heteroatoms independently selected from the group consisting of N, NH, N-oxide, O, or S;
  • T is C 1 to Cs alkylene wherein one or two -CH 2 - groups are optionally replaced with -NR 0 -, -S-, or -O- and optionally two -CH 2 - groups together form a double bond provided that T does not contain an -O-O-, -S-O-, or -S-S- group;
  • R a is independently selected from the group consisting of hydrogen, alkyl, and substituted alkyl
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic or, alternatively, R and R together with the nitrogen atom pendent thereto, form a heterocyclic, a substituted heterocyclic, a heteroaryl or a substituted heteroaryl ring group;
  • R and R are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or, alternatively, R 2 and R 2 as defined are taken together with the carbon atom pendent thereto to form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group, or, still further alternatively, one of R 2 or R 2 is hydrogen, alkyl or substituted alkyl, and the other is joined, together with the carbon atom pendent thereto, with either the R and the oxygen atom pendent thereto or R and the nitrogen atom pendent thereto to form a heterocyclic or substituted heterocyclic group;
  • R is selected from hydrogen and alkyl or, when R and R are not taken together to form a ring and when R 2 or R 2 and R 7 or R 8 are not joined to form a heterocyclic or substituted heterocyclic group, then R 3 , together with the nitrogen atom pendent thereto, may be taken together with one of R 2 and
  • R 2 to form a heterocyclic or substituted heterocyclic ring group
  • R 25 , R 26 and R 27 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R 25 and R 26 together with the carbon atom pendent thereto form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; and
  • Y is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, halo, hydroxy, nitro, aryl, heteroaryl, substituted aryl, and substituted heteroaryl;
  • J and K are independently selected from the group consisting of N, NH, CX, and N- oxide provided that J and K are not both CX;
  • W 1 , W 2 , W 3 , W 4 , W 5 , and W 6 are independently selected from the group consisting of N, N-oxide, or CX, provided that no more than one of J, K, and W 1 -W 6 is an N-oxide and provided that one of W 4 or W 5 is C-Y; each X is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, halo, hydroxy, and nitro;
  • T is C 1 to C 5 alkylene wherein one or two -CH 2 - groups are optionally replaced with -NR 0 -, -S-, or -O- and optionally two -CH 2 - groups together form a double bond provided that T does not contain an -O-O-, -S-O-, or -S-S- group;
  • R a and R c are independently selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic or, alternatively, R 8 and R 9 together with the nitrogen atom pendent thereto, form a heterocyclic, a substituted heterocyclic, a heteroaryl or a substituted heteroaryl ring group;
  • R and R are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or, alternatively, R 2 and R 2 as defined are taken together with the carbon atom pendent thereto to form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group, or, still further alternatively, one of R or R is hydrogen, alkyl or substituted alkyl, and the other is joined, together with the carbon atom pendent thereto, with either the R 7 and the oxygen atom pendent thereto or R 8 and the nitrogen atom pendent thereto to form a heterocyclic or substituted heterocyclic group; R is selected from hydrogen and alkyl or, when R and R are not taken together to
  • R 25 , R 26 and R 27 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R 25 and R 26 together with the carbon atom pendent thereto form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; and
  • J is CX or N
  • Z, Q, R b , n, m, W 7 , Y are previous defined.
  • Y is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, halo, hydroxy, nitro, aryl, heteroaryl, substituted aryl, and substituted heteroaryl;
  • J and K are independently selected from the group consisting of N, NH, CX, and N- oxide provided that J and K are not both CX; when L is C, P is NH; when L is N, P is N or CX and W 7 is CH or CH 2 ;
  • W 3 , W 4 , W 5 , and W 6 are independently selected from the group consisting of N, N- oxide, or CX, provided that no more than one of J, K, and W 3 -W 6 is an N-oxide and provided that one of W 4 or W 5 is C-Y; m is 0, 1, or 2; the line ⁇ 111 represents a single bond when W 7 is N or CH 2 or a double bond when W 7 is CH;
  • W 7 is selected from the group consisting of CH, CH 2 , and NR C ; each X is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, halo, hydroxy, and nitro;
  • R a and R c are independently selected from the group consisting of hydrogen, alkyl, and substituted alkyl;
  • Z is selected from the group consisting of (a) carboxy and carboxy ester
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic or, alternatively, R 8 and R 9 together with the nitrogen atom pendent thereto, form a heterocyclic, a substituted heterocyclic, a heteroaryl or a substituted heteroaryl ring group;
  • R 11 is hydrogen or alkyl
  • R 1 is selected from -OR 7 and -NR 8 R 9 where R 7 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; R and R are as defined above; R and R are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or, alternatively, R 2 and R 2 as defined are taken together with the carbon atom pendent thereto to form a cycloalkyl, substituted cycloalkyl, heterocyclic or
  • R is selected from hydrogen and alkyl or, when R and R are not taken together to form a ring and when R or R and R or R are not joined to form a heterocyclic or substituted heterocyclic group, then R 3 , together with the nitrogen atom pendent thereto, may be taken together with one of R 2 and
  • R 2 to form a heterocyclic or substituted heterocyclic ring group
  • R 25 , R 26 and R 27 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R 25 and R 26 together with the carbon atom pendent thereto form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; and
  • P is CH.
  • J is CH.
  • J is N.
  • E is S. In other embodiments, D is CH and E is S.
  • R a is hydrogen. In other embodiments, R a is substituted alkyl, substituted amino, or substituted aminoalkyl. In some aspects, R a is selected from the following substituents:
  • Z is a carboxylic acid isostere.
  • the carboxylic acid isostere is a carboxylic acid bioisostere.
  • the carboxylic acid isostere is selected from lH-tetrazol-5-yl and 5-oxo-4,5-dihydro-l,2,4- oxadiazol-3-yl.
  • R is substituted alkyl.
  • the substituted alkyl comprises 1 to 2 substituents selected from the group consisting of sulfonic acid (SO 3 ⁇ ), carboxy, carboxy ester, amino, substituted amino, aryl, substituted aryl, heteroaryl and substituted heteroaryl.
  • the substituted alkyl group is selected from the group consisting of 3,4-dimethoxybenzyl, 3,4-dihydroxybenzyl, 3-methoxy-4- hydroxybenzyl, 4-aminosulfonylbenzyl, 4-methylsulfonylbenzyl, (1 -methyl -piperidin-3- yl)methyl, (1 -methyl -pyrrolidin-3-yl)methyl, fur-2-ylmethyl, 6-methylpyridin-2-ylmethyl, 2-(l-methyl-pyrrolidin-3-yl)ethyl, 1-phenylethyl, l-(3-methoxyphenyl)-ethyl, l-(4-methoxyphenyl)-ethyl, N',N'-dimethylaminoethyl, and 2-(lH-pyrazol-l-yl)eth
  • Z is selected from N-methyl carboxamide, N,N- dimethylcarboxamido, N-isopropyl-carboxamido, N-allyl-carboxamido, and 5-hydroxy- tryptophan-carbonyl.
  • R 9 is substituted aryl.
  • R 9 is selected from the group consisting of 7- hydroxynaphth-1-yl, 6-hydroxynaphth-l-yl, 5-hydroxynaphth-l-yl, 6-carboxynaphth-2-yl, (4-HOOCCH 2 -)phenyl, (3,4-dicarboxy)phenyl, 3-carboxyphenyl, 3-carboxy-4- hydroxyphenyl and 2-biphenyl.
  • R 9 is substituted heteroaryl.
  • the substituted heteroaryl is selected from the group consisting of 4-methyl-2-oxo-2H-chromen- 7-yl, l-phenyl-4-carboxy-l ⁇ -pyrazol-5-yl, 5-carboxypyrid-2-yl, 2-carboxypyrazin-3-yl, and 3-carboxythien-2-yl.
  • the heterocyclic group is N-morpholino, tetrahydrofuranyl, and 1,1-dioxidotetrahydrothienyl.
  • the heterocyclic and substituted heterocyclic rings comprise 4 to 8 membered rings containing 1 to 3 heteroatoms.
  • the 1 to 3 heteroatoms comprises 1 to 2 nitrogen atoms.
  • the heterocyclic or substituted heterocyclic ring is selected from the group consisting of piperidine, substituted piperidine, piperazine, substituted piperazine, morpholino, substituted morpholino, thiomorpholino and substituted thiomorpholino wherein the sulfur atom of the thiomorpholino or substituted thiomorpholino ring is optionally oxidized to provide for sulfoxide and sulfone moieties.
  • the heterocyclic or substituted heterocyclic ring is selected from the group consisting of piperidine, substituted piperidine, piperazine, substituted piperazine, morpholino, substituted morpholino, thiomorpholino and substituted thiomorpholino wherein the sulfur atom of the thiomorpholino or substituted thiomorpholino ring is optionally
  • the heterocyclic or substituted heterocyclic ring is selected from the group consisting of 4-hydroxypiperidin-l-yl, l,2,3,4-tetrahydro-3- carboxy-isoquinolin-2-yl, 4-methylpiperizin-l-yl, morpholin-4-yl, thiomorpholin-4-yl , A- methyl-piperazin-1-yl, and 2-oxo-piperazinyl.
  • R 2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.
  • R 2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, and substituted cycloalkyl.
  • R 2 is selected from the group consisting of hydrogen, methyl, 1-methylprop-l-yl, sec -butyl, hydroxymethyl, 1- hydroxyeth-1-yl, 4-amino-n-butyl, 2-carboxyeth-l-yl, carboxymethyl, benzyl, (IH- imidazol-4-yl)methyl, (4-phenyl)benzyl, (4-phenylcarbonyl)benzyl, cyclohexylmethyl, cyclohexyl, 2-methylthioeth-l-yl, ⁇ o-propyl, carbamoylmethyl, 2-carbamoyleth-l-yl, (4-hydroxy)benzyl, and 3-guanidino-n-propyl.
  • R 1 is selected from the group consisting of hydroxy, alkoxy, amino(N-morpholino), amino, and substituted amino.
  • R 1 is selected from the group consisting of hydroxy, alkoxy, amino(N-morpholino), amino, and substituted amino, and R and R , together with the carbon atom and nitrogen atom bound thereto respectively, are joined to form a heterocyclic or substituted heterocyclic group.
  • R 1 is selected from the group consisting of hydroxy, alkoxy, amino(N-morpholino), amino, and substituted amino and R 2 and R 3 , together with the carbon atom and nitrogen atom bound thereto respectively, are joined to form a heterocyclic or substituted heterocyclic group, the heterocyclic and substituted heterocyclic groups are selected from the group consisting of pyrrolidinyl, 2- carboxy-pyrrolidinyl, 2-carboxy-4-hydroxypyrrolidinyl, and 3-carboxy-l,2,3,4- tetrahydroisoquinolin-3-yl.
  • Z is selected from 1-carboxamidocyclopent-l- ylaminocarbonyl, 1 -carboxamido- 1 -methyl-eth- 1 -ylaminocarbonyl, 5 -carboxy- 1 ,3 -dioxan- 5 -ylaminocarbonyl, 1 -(N-methylcarboxamido)- 1 -(methyl)-eth- 1 -ylaminocarbonyl, 1 -(N ,N- dimethylcarboxamido)- 1 -(methyl)-eth- 1 -ylaminocarbonyl, 1 -carboxy- 1 -methyl-eth- 1 - ylaminocarbonyl, l-(N-methylcarboxamido)-cyclobutanaminocarbonyl, 1 -carboxamido- cyclobutanaminocarbonyl, l-(N,N-dimethylcarboxamido)-cyclobut
  • Z is -C(O)NR 21 S(O) 2 R 4 .
  • R 4 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.
  • R 4 is methyl, ethyl, isopropyl, propyl, trifluoromethyl, 2,2,2- trifluoroethyl, phenyl, benzyl, phenethyl, 4-bromophenyl, 4-nitrophenyl or 4-methylphenyl, 4-methoxyphenyl, 2-aminoethyl, 2-(dimethylamino)ethyl, 2-N-benzyloxyaminoethyl, pyridinyl, thienyl, 2-chlorothien-5-yl, 2-methoxycarbonylphenyl, naphthyl, 3-chlorophenyl, 2-bromophenyl, 2-chlorophenyl, 4-trifluoromethoxyphenyl, 2,5-difluorophenyl, 4- fluorophenyl, 2-methylphenyl, 6-ethoxybenzo[
  • Z is selected from hydrogen, halo, alkyl, alkoxy, amino, substituted amino, and cyano.
  • Z is -C(X 2 )-N(R 3 )CR 25 R 26 R 27 , wherein X 2 and R 3 are defined above, and R , R and R are alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R 25 and R 26 together with the carbon atom pendent thereto form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group.
  • Z is selected from l-(6-(3-carboxyprop-2-en-l-yl)-lH- benzo[d]imidazol-2-yl)cyclobutanaminocarbonyl, 3-(6-(3-carboxyprop-2-en-l-yl)-l ⁇ - benzo[ ⁇ i]imidazol-2-yl)- 1 -methylpyrrolidin-3-aminocarbonyl, 1 -(I -methyl-6-(3- carboxyprop-2-en-l-yl)-lH-benzo[(i]imidazol-2-yl)cyclobutanaminocarbonyl, 1- (benzofuran-2-yl)-5-carboxy-cyclobutanaminocarbonyl, l-(2-methylthiazol-4-yl)- cyclobutanaminocarbonyl, 1 -(2-acetylamino-thiazol-4-yl)-cyclobutanamino,
  • Z is carboxy, carboxy ester, carboxylic acid isostere, -C(O)NR 8 R 9 , or -C(O)NHS(O) 2 R 4 , wherein R 8 and R 9 are as defined above and R 4 is alkyl or aryl.
  • Z is carboxy, methyl carboxylate, ethyl carboxylate, 6-( ⁇ -D- glucuronic acid) ester, lH-tetrazol-5-yl, 5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl, N-2- cyano-ethylamide, N-2-(l ⁇ -tetrazol-5-yl)ethylamide, methylsulfonylaminocarbonyl, trifluoromethylsulfonylaminocarbonyl, or phenylsulfonylaminocarbonyl.
  • Z is carboxy.
  • Z is selected from the group consisting of
  • Y is substituted aryl or substituted heteroaryl.
  • Y is selected from the group consisting of substituted biphenyl, substituted phenyl, substituted 6-membered heteroaryl ring optionally fused to a phenyl ring and having one, two, or three heteroatoms independently selected from the group consisting of N, O, or S wherein the heteroatoms N or S are optionally oxidized, and substituted 5-membered heteroaryl ring optionally fused to a phenyl ring and having one, two, or three heteroatoms independently selected from the group consisting of N, O, or S wherein the heteroatoms N or S are optionally oxidized.
  • Y is substituted 5-membered heteroaryl ring optionally fused to a phenyl ring and having one, two, or three heteroatoms independently selected from the group consisting of N, O, or S wherein the heteroatoms N or S are optionally oxidized.
  • -Y is -Ar 1 -(G 1 ) q
  • Ar 1 is selected from arylene and heteroaryl ene
  • G 1 is selected from halo, hydroxy, nitro, cyano, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, aminoacyl, amino, substituted amino, carboxy and carboxy ester
  • q is an integer from 1 to 3.
  • -Y is -Ar 1 - (G 1 X 1 )
  • Ar 1 is selected from phenyl, thiazolyl, furanyl, thienyl, pyridinyl, pyrazinyl, oxazolyl, isoxazolyl, pyrrolyl, imidazolyl, and pyrrolidinyl.
  • G 1 is selected from bromo, chloro, methyl, hydroxy, methoxy, ethoxy, acetyl, acetamido, carboxy, and amino.
  • Y is selected from 2,4- dimethylthiazol-5-yl, 3-bromo-4-aminophenyl, 3-amido-4-hydroxy-phenyl, 2-hydroxy-6- methoxy-phenyl, 4-(acetylamino)-phenyl, 2,4-dihydroxyphenyl, 2,4-dimethoxy-6- hydroxyphenyl, and 7-hydroxybenzofuranyl.
  • Y is -Ar 1 -Ar 2 - where the -Ar ⁇ Ar 2 - group is selected from the group consisting of-aryl-aryl, -aryl-substituted aryl, -substituted aryl-aryl, -substituted aryl-substituted aryl, -aryl-heteroaryl, -aryl-substituted heteroaryl, -substituted aryl-heteroaryl, -substituted aryl-substituted heteroaryl, heteroaryl-aryl, heteroaryl-substituted aryl, substituted heteroaryl-aryl, substituted heteroaryl-substituted aryl, -aryl-cycloalkyl, -aryl-substituted cycloalkyl, -substituted aryl-cycloalkyl, -substituted aryl,
  • the -Ar ! -Ar 2 - group is selected from the group consisting of 4'-chloro-4-methoxybiphen-2-yl, biphen-2-yl, biphen-4-yl, 4-amino- 4'-chlorobiphen-2-yl, 4'-aminomethyl-4-methoxybiphen-2-yl, 4-carbamoyl-4'- methoxybiphen-2-yl, 4-carbamoyl-4'-fluorobiphen-2-yl, 4-carbamoyl-4'-methoxybiphen-2- yl, 4-carbamoyl-4'-nitrobiphen-2-yl, 4-(carbamoylmethyl-carbamoyl)biphen-2-yl, 4- (carbamoylmethylcarbamoyl)-4'-chlorobiphen-2-yl, 4-carboxy-4'-chlorobiphen-2-yl, 4-carboxy-4'-chlorobi
  • the -Ar -Ar group is selected from the group consisting of 4-(lH-imidazol-l-yl)phenyl, 2-furan-2-yl-5-methoxyphenyl, 5- methoxy-2-thiophen-2-ylphenyl, 2-(2,4-dimethoxypyrimidin-5-yl)-4-methoxyphenyl, 2- (pyrid-4-yl)phenyl, 3 -amino-5 -phenylthiophen-2-yl, 5 -(4-chlorophenyl)-2-methylfuran-2-yl, 3-(4-chlorophenyl)-5-methylisoxazol-4-yl, 2-(4-chlorophenyl)-4-methylthiazol-5-yl, 3 -(3, 4- dichloro-phenyl)isoxazol-5-yl, 3,5-dimethyl-l-phenyl-lH
  • the -Ar ! -Ar 2 - group is selected from the group consisting of 2-cyclohexyl- ⁇ /, ⁇ /-dimethylamino-carbonylmethyl-5- methoxyphenyl, and 4-morpholinophenyl.
  • Y is is selected from the group consisting of substituted quinolyl, substituted benzofuryl, substituted thiazolyl, substituted furyl, substituted thienyl, substituted pyridinyl, substituted pyrazinyl, substituted oxazolyl, substituted isoxazolyl, substituted pyrrolyl, substituted imidazolyl, substituted pyrrolidinyl, substituted pyrazolyl, substituted isothiazolyl, substituted 1,2,3-oxadiazolyl, substituted 1,2,3-triazolyl, substituted 1,3,4-thiadiazolyl, substituted pyrimidinyl, substituted 1,3,5-triazinyl, substituted indolizinyl, substituted indolyl, substituted isoindolyl, substituted indazolyl, substituted benzothienyl, substituted benzthiazolyl, substituted purinyl, substituted quinolizin
  • Y is substituted with one to three subsitutents independently selected from the group consisting of alkyl, haloalkyl, halo, hydroxy, nitro, cyano, alkoxy, substituted alkoxy, acyl, acylamino, aminoacyl, amino, substituted amino, carboxy, and carboxy ester.
  • Y is 2,4- dimethylthiazol-5-yl. In some embodiments, Y is selected from
  • Y is selected from the corresponding Y groups in Table 1.
  • n is 1 and R b is oxo.
  • n is 2 and both R b are hydroxy.
  • R b is -C(O)NR 12 R 13 wherein R 12 and R 13 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, -(CH 2 ) 0 -3R 16 , and -NR 17 R 18 , or R 12 and R 13 and the nitrogen atom to which they are attached form a substituted or unsubstituted heterocyclic ring provided that both R 12 and R 13 are not both hydrogen; wherein R 16 is aryl, heteroaryl, or heterocyclic; and R 17 and R 18 are independently hydrogen or alkyl or R 17 and R together with the nitrogen atom to which they are attached join to form a heterocyclic ring with 4 to 7 ring atoms. In some aspects, R 12 and R 13 together form a morpholino ring.
  • T is - CH 2 CH 2 NR 0 CH 2 -. In some embodiments, T is - CH 2 CH 2 CH 2 CH 2 -.
  • n is 0. In some embodiments, m is 1. In some embodiments, m is 2.
  • W 7 is O. In some aspects, m is 1.
  • W 7 is CH. In some aspects, m is 0. In other aspects, m is 1. In some embodiments, W 7 is NR C . In some aspects, m is 1. In other aspects, m is 2.
  • R c is hydrogen. In other aspects R c is alkyl substituted with heterocyclyl or substituted heterocyclyl. In still other aspects R c is -C(O)O(alkyl).
  • R c is selected from
  • R c is C v H 2v -C(O)-NR 12 R 13 where v is 1, 2 or 3;
  • R 12 and R 13 are selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl alkoxy, substituted alkoxy and -(CH 2 )o_3R 16 ;
  • R 16 is aryl, heteroaryl, heterocyclic, -NR R ; and R and R are independently selected from hydrogen, and alkyl, or alternatively, R 17 and R 18 together with the nitrogen atom to which they are attached join to form a heterocyclic ring with 4 to 7 ring atoms; or, alternatively, R 12 and R 13 and the nitrogen atom to which they are attached form a heterocyclic or substituted heterocyclic ring; provided that both R 12 and R 13 are not alkoxy and/or substituted alkoxy.
  • v is 1.
  • the NR 12 R 13 group is selected from N,N-dimethylamino-carbonylmethyl, [N-(4-hydroxy-l,l- dioxidotetrahydro-3 -thienyl)amino] -carbonylmethyl, (cyclopropylmethylamino)- carbonylmethyl, (prop-2-yn- 1 -ylamino)-carbonylmethyl, (2-(morpholino)eth- 1 -ylamino)- carbonylmethyl, (phenylsulfonylamino)-carbonylmethyl, [N-benzylamino]-carbonylmethyl, (N-(4-methylsulfonyl-benzyl)amino)-carbonylmethyl, (tryptophanyl)-carbonylmethyl, (tyrosine)-carbonylmethyl, (N-( 1 )
  • R c is selected from morpholinocarbonylmethyl, N,N- dimethylaminocarbonylmethyl, (4-pyrrolidinyl-piperidin- 1 -yl)carbonylmethyl, piperazinylcarbonylmethyl.
  • R c is an oxide of morpholinocarbonylmethyl, ⁇ /, ⁇ /-dimethylaminocarbonylmethyl, (4-pyrrolidinyl-piperidin- 1 -yl)carbonylmethyl, piperazinylcarbonylmethyl.
  • R c is selected from [(N,N-dimethylamino)prop-2-en-l-yl]- carbonylmethyl, (N,N-dimethylpiperidin-4-aminium trifluoroacetate)acetyl, 2-(N 5 N- dimethylpiperidin-4-aminium trifluoroacetate)morpholino acetyl, (2-(diisopropyl)eth-l-yl)- carbonylmethyl, (pyridin-4-ylcarbonylhydrazino)-carbonylmethyl, (N-(4-carboxybenzyl)- amino)carbonylhydrazino)-carbonylmethyl, (acetylhydrazino)-carbonylmethyl, ((N',N'- dimethylaminomethyl-carbonyl)hydrazino)-carbonylmethyl.
  • R c is substituted alkyl, wherein said substituted alkyl is selected from the group consisting of aminoalkyl, substituted aminoalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, -CH 2 COOH, and -CH 2 CONR 12 R 13 , wherein R 12 and R 13 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, -(CH 2 ) 0 _ 3 R 16 , and -NR 17 R 18 , or R 12 and R 13 and the nitrogen atom to which they are attached form a substituted or unsubstituted heterocyclic ring provided that both R 12 and R 13 are not both hydrogen; wherein R 16 is aryl, heteroaryl
  • R c is -CH 2 CONR 12 R 13 and at least one of R 12 or R 13 is alkyl, substituted alkyl, or heteroaryl. In some aspects at least one of R or R is methyl, carboxymethyl, 2-hydroxyethyl, 2-morpholin-4-ylethyl, or tetrazoyl-5-yl. In other aspects R is l-methyl-piperidin-4-yl, l-methyl-piperidin-3-ylmethyl, and thiazol-2-yl carbamoyl methyl.
  • R c is -CH 2 CONR 12 R 13 and R 12 and R 13 and the nitrogen atom to which they are attached form a substituted or unsubstituted heterocyclic ring.
  • R 12 and R 13 and the nitrogen atom to which they are attached form a substituted or unsubstituted morpholino, substituted or unsubstituted piperidinyl, or a substituted or unsubstituted pyrrolidinyl ring.
  • substituted or unsubstituted morpholino, piperidinyl, or pyrrolidinyl ring is selected from the group consisting of morpholino, 4-pyrrolidin-l-yl-piperidinyl, piperidinyl, 4-hydroxypiperidinyl, 4-carboxypiperidinyl, 4-dimethylaminopiperidinyl, 4-diethylaminopiperidinyl, 2- methylpyrrolidinyl, 4-morpholin-4-yl -piperidinyl, 3,5-dimethyl-morpholin-4-yl, 4- methylpiperidinyl.
  • the present invention further provides metabolites of any of compounds of Formula (A), (I), (II), (III), (IV), (Ia)-(If), (Ha)-(IIf), (IVa) or the compounds in Table 1.
  • the metabolite is an oxide.
  • compositions comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of one of the compounds described herein or mixtures of one or more of such compounds.
  • This invention is further directed to methods for treating a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, such as HCV, in mammals which methods comprise administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of one of the compounds described herein or mixtures of one or more of such compounds.
  • present invention provides for use of the compounds of the invention for the preparation of a medicament for treating or preventing said infections.
  • the mammal is a human.
  • agents active against HCV include ribavirin, levovirin, viramidine, thymosin alpha- 1, an inhibitor of NS3 serine protease, and inhibitor of inosine monophosphate dehydrogenase, interferon-alpha, pegylated interferon-alpha, alone or in combination with ribavirin or viramidine.
  • the additional agent active against HCV is interferon-alpha or pegylated interferon-alpha alone or in combination with ribavirin or viramidine.
  • the compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
  • Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein. If the compounds of this invention contain one or more chiral centers, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures.
  • stereoisomers and enriched mixtures are included within the scope of this invention, unless otherwise indicated.
  • Pure stereoisomers may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art.
  • racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.
  • the compounds of the invention may generally be prepared via a transition metal catalyzed cross-coupling reaction as shown above in Scheme A where L and L' are suitable cross-coupling substituents, P' is hydrogen, a nitrogen protecting group and Z, D, E, Q, ring H, and ring I are as previously defined.
  • L or L' is a Sn, B, Zr, or Zn based metal (e.g. -BOH 2 , Sn(CH 3 ) 3 , etc.) and the other of L or L' is a leaving group such as halogen or sulfonate.
  • Suitable halogens and sulfonates include Cl, Br, I, -OSO 2 CF 3 , and -OSO 2 CH 3 .
  • Suitable transition metal catalysts include Pd and Ni based catalysts (e.g. Pd(PPh 3 ) 2 C1 2 , Pd[P(Ph 3 )J 4 , etc.).
  • one of A.1 or A.2 has L is -B(OH) 2 and is prepared by treating a compound of A.1 or A.2 where L or L' is halogen with an excess of bis(neopentylglycolato)diboron in the presence of a catalytic amount of triphenylphosphine palladium(II) di chloride.
  • the resulting boronic acid is the coupled with the other of A.1 or A.2 where L is halogen or a sulfonate under Suzuki coupling conditions.
  • Suitable coupling conditions include reaction of A.1 and A.2 in refluxing methanol containing Pd[P(Ph) 3 J 4 and NaHCO 3 for 10 to 20 hours.
  • the coupled product can then be further modified to yield the compounds of the invention using methods that will be apparent to one of skill in the art as illustrated in the following Schemes.
  • Scheme 1 shows the synthesis of compounds where Z is COOH, Q is cyclohexyl, rings H and I are as depicted, and T is -CH 2 - substituted with OH.
  • Compound 1.4 is formed following Suzuki coupling of 1.1 and 1.2 to form the five membered central ring and saponification of 1.3 under basic conditions such as with NaOH.
  • Scheme 2 shows the synthesis of compounds where Z is COOH, Q is cyclohexyl, rings H and I are as depicted, and T is a substituted alkylene that forms a central six member ring.
  • Suzuki coupling of 2.1 with 2.2 gives the coupled indole 2.3 that is then deprotonated with a base such as NaH and alkylated with acyl dichloride 2.4.
  • the resulting chloride 2.5 is metallated such as by treatment with n-BuLi to effect intramolecular ring closure to give 2.6. Saponification of the resulting compound under basic conditions give 2.7.
  • Scheme 3 shows the synthesis of compounds where Z is
  • Scheme 4 shows the synthesis of compounds where Z is COOH, Q is cyclohexyl, rings H and I are as depicted, and T is a substituted alkylene that forms a central seven member ring.
  • Bromoindole derivative 4.1 is converted to the corresponding boronic acid 4.2 using bis(neopentyl)diboron and a palladium(O) catalyst.
  • Suzuki coupling of the boronic acid 4.2 with allyl substituted aryl bromide 4.3 gives the biaryl product 4.4.
  • Base catalyzed N-allylation of indole 4.4 with allyl bromide gives the di-N-allyl product 4.5.
  • the ring closure metathesis (RCM) reaction of the di-N-allyl compound 4.5 gives the 7-membered carbacyclic product 4.6.
  • the ruthenium catalyst also commonly known as “Grubb's catalyst” or benzylidene- bis(tricyclohexylphosphine)dichlororuthenium, is commercially available from Sigma Aldrich.
  • Several other commercially available metallocarbene complexes of metals such as Ruthenium and Molybdenum can also be used in this reaction. Hydrogenation of 4.6 gives 4.7 that is then saponified to 4.8.
  • Scheme 5 shows the synthesis of compounds where Z is COOH, Q is cyclohexyl, rings H and I are as depicted, and T is -CH 2 CH 2 O- that forms a central seven member ring.
  • Boronic acid 5.1 is coupled with bromide 5.2 under Suzuki coupling conditions to give 5.3.
  • Treatment of 5.3 with NaH and 1 ,2-dibromoethane gives 5.4 that is then saponified to yield 5.5.
  • Scheme 6 shows the synthesis of compounds where Z is COOH, Q is cyclohexyl, rings H and I are as depicted, and T is -CH 2 C(O)NH- that forms a central seven member ring.
  • Indole 6.1 is deprotonated and alkylated with 6.2 to give bromide 6.3 that is then coupled to boc (tert-butyloxycarbonyl) protected boronic acid 6.4 in the presence of a palladium(O) catalyst such as triphenylphosphine palladium(II) dichloride.
  • Treatment of 6.5 with TFA (trifluoro acetic acid) effects ring closure to form lactam 6.6 that is saponifed under basic conditions such as with LiOH to give 6.7.
  • Scheme 7 shows the synthesis of compounds where Z is COOH, Q is cyclohexyl, rings H and I are as depicted, and T forms a central eight member ring.
  • Bromoindole derivative 7.1 is converted to the corresponding boronic acid 7.2 using bis(neopentyl)diboron and a palladium(O) catalyst.
  • Suzuki coupling of the boronic acid 7.2 with 7.3 gives the biaryl product 7.4 followed by reductive amination with amine 7.5 and NaBHsCN to give 7.6.
  • Hydrolysis of the t-butyl ester group with trifluroroacetic acid gives acid 7.7 that is then cyclized to give amide 7.8.
  • the ring closure can be affected with an amide coupling reagent such as HATU (N-[(dimethylamino)-lH-l,2,3-triazolo[4,5- b]pyridine- 1 -ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide).
  • HATU N-[(dimethylamino)-lH-l,2,3-triazolo[4,5- b]pyridine- 1 -ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide.
  • Scheme 8 illustrates the conversion of 2- bromoindole derivatives to the corresponding indol-2-yl boronic acid.
  • reaction 8.2, by contact with an excess of bis(neopentylglycolato)diboron in the presence of a catalytic amount of triphenylphosphine palladium(II) dichloride.
  • a suitable solvent such as DMSO
  • a suitable base such as potassium acetate
  • the reaction is conducted at a temperature of from about 60 0 C to about 120 0 C.
  • the reaction is continued until it is substantially complete which typically occurs within about 0.5 to 15 hours.
  • Scheme 10 shows the synthesis of compounds where Z is COOH, Q is cyclohexyl, rings H and I form a benzimidazole group, and T is an alkylene chain where m is 0, 1, or 2.
  • Bromide 10.1 synthesized as described in WO 2003010141 is reacted with bis(pinacolato)diboron and catalytic Pd(PPh S ) 2 Cl 2 to give ester 10.2 that is then coupled with 2-bromobenzimidazole under Suzuki coupling conditions to give 10.3.
  • Treatment of 10.3 with a base such as NaH and a dihaloalkane such as a diiodioalkane gives a cyclized intermediate that is then saponified to yield 10.4.
  • Scheme 11 shows the synthesis of compounds where Z is COOH, Q is cyclohexyl, rings H and I form an indole group, and T is an alkylene chain where m is 0, 1, or 2.
  • Bromide 10.1 is reacted with an indole boronic acid and catalytic Pd(PPh S ) 2 Cl 2 under Suzuki coupling conditions to give 11.2.
  • Treatment of 11.2 with a base such as NaH and a dihaloalkane such as a diiodioalkane gives a cyclized intermediate that is then saponified to yield 11.3.
  • the present invention provides novel compounds possessing antiviral activity, including Flaviviridae family viruses such as hepatitis C virus.
  • Flaviviridae family viruses such as hepatitis C virus.
  • the compounds of this invention inhibit viral replication by inhibiting the enzymes involved in replication, including RNA dependent RNA polymerase. They may also inhibit other enzymes utilized in the activity or proliferation of Flaviviridae viruses.
  • the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
  • the actual amount of the compound of this invention, i.e., the active ingredient will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.
  • the drug can be administered more than once a day, preferably once or twice a day.
  • Therapeutically effective amounts of compounds of the present invention may range from approximately 0.01 to 50 mg per kilogram body weight of the recipient per day; preferably about 0.01-25 mg/kg/day, more preferably from about 0.1 to 10 mg/kg/day.
  • the dosage range would most preferably be about 7-70 mg per day.
  • This invention is not limited to any particular composition or pharmaceutical carrier, as such may vary.
  • compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • routes oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • the preferred manner of administration is oral using a convenient daily dosage regimen that can be adjusted according to the degree of affliction.
  • compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
  • Another preferred manner for administering compounds of this invention is inhalation.
  • the choice of formulation depends on various factors such as the mode of drug administration and bioavailability of the drug substance.
  • the compound can be formulated as liquid solution, suspensions, aerosol propellants or dry powder and loaded into a suitable dispenser for administration.
  • suitable dispenser for administration There are several types of pharmaceutical inhalation devices-nebulizer inhalers, metered dose inhalers (MDI) and dry powder inhalers (DPI).
  • MDI metered dose inhalers
  • DPI dry powder inhalers
  • Nebulizer devices produce a stream of high velocity air that causes the therapeutic agents (which are formulated in a liquid form) to spray as a mist that is carried into the patient's respiratory tract.
  • MDFs typically are formulation packaged with a compressed gas.
  • the device Upon actuation, the device discharges a measured amount of therapeutic agent by compressed gas, thus affording a reliable method of administering a set amount of agent.
  • DPI dispenses therapeutic agents in the form of a free flowing powder that can be dispersed in the patient's inspiratory air-stream during breathing by the device.
  • the therapeutic agent In order to achieve a free flowing powder, the therapeutic agent is formulated with an excipient such as lactose.
  • a measured amount of the therapeutic agent is stored in a capsule form and is dispensed with each actuation.
  • compositions are comprised of in general, a compound of the present invention in combination with at least one pharmaceutically acceptable excipient.
  • Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the claimed compounds.
  • excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
  • Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
  • Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
  • Preferred liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
  • Compressed gases may be used to disperse a compound of this invention in aerosol form.
  • Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
  • Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
  • the amount of the compound in a formulation can vary within the full range employed by those skilled in the art.
  • the formulation will contain, on a weight percent (wt%) basis, from about 0.01-99.99 wt% of a compound of the present invention based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
  • the compound is present at a level of about 1-80 wt%. Representative pharmaceutical formulations are described in the Formulation Examples section below.
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of another active agent against RNA- dependent RNA virus and, in particular, against HCV.
  • Agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha- 1, an inhibitor of HCV NS3 serine protease, or an inhibitor of inosine monophosphate dehydrognease, interferon- ⁇ , pegylated interferon- ⁇ (peginterferon- ⁇ ), a combination of interferon- ⁇ and ribavirin, a combination of peginterferon- ⁇ and ribavirin, a combination of interferon- ⁇ and levovirin, and a combination of peginterferon- ⁇ and levovirin.
  • Interferon- ⁇ includes, but is not limited to, recombinant interferon- ⁇ 2a (such as ROFERON interferon available from Hoffman-LaRoche, Nutley, NJ), interferon- ⁇ 2b (such as Intron-A interferon available from Schering Corp., Kenilworth, New Jersey, USA), a consensus interferon, and a purified interferon- ⁇ product.
  • interferon- ⁇ 2a such as ROFERON interferon available from Hoffman-LaRoche, Nutley, NJ
  • interferon- ⁇ 2b such as Intron-A interferon available from Schering Corp., Kenilworth, New Jersey, USA
  • a consensus interferon such as Intron-A interferon available from Schering Corp., Kenilworth, New Jersey, USA
  • the agents active against hepatitis C virus also include agents that inhibit HCV proteases, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and inosine 5 '-monophosphate dehydrogenase.
  • Other agents include nucleoside analogs for the treatment of an HCV infection.
  • Still other compounds include those disclosed in WO 2004/014313 and WO 2004/014852 and in the references cited therein.
  • the patent applications WO 2004/014313 and WO 2004/014852 are hereby incorporated by references in their entirety.
  • Specific antiviral agents include Omega IFN (BioMedicines Inc.), BILN-2061 (Boehringer Ingelheim), Summetrel (Endo Pharmaceuticals Holdings Inc.), Roferon A (F. Hoffman-La Roche), Pegasys (F. Hoffman-La Roche), Pegasys/Ribaravin (F. Hoffman-La Roche), CellCept (F.
  • compositions and methods of the present invention contain a compound of the invention and interferon.
  • the interferon is selected from the group consisting of interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau.
  • compositions and methods of the present invention contain a compound of the invention and a compound having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiquimod, ribavirin, an inosine 5'monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
  • a compound having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiquimod, ribavirin, an inosine 5'monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
  • the compound having anti-HCV activity is Ribavirin, levovirin, viramidine, thymosin alpha- 1, an inhibitor of NS3 serine protease, and inhibitor of inosine monophosphate dehydrogenase, interferon-alpha, or pegylated interferon-alpha alone or in combination with Ribavirin or viramidine.
  • the compound having anti-HCV activity is said agent active against HCV is interferon-alpha or pegylated interferon-alpha alone or in combination with Ribavirin or viramidine.
  • DMEM Dulbeco's Modified Eagle's Medium
  • EDTA ethylenediaminetetraacetic acid
  • HCV hepatitus C virus
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • NTA nitrilotriacetic acid
  • NTP nucleoside triphosphate
  • Tris Tris(hydroxymenthyl)aminomethane
  • Step 3 Synthesis of Compound 225
  • a reaction vessel was charged with 97 mg (0.26 mmol) 10.3 and dissolved with 10 mL DMF. NaH (31 mg, 0.78 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 15 min. 1,3-diiodopropane (37 ⁇ L, 0.33 mmol, 1.25 eq) was then added via syringe and the reaction mixture was allowed to continue stirring at room temperature. HPLC and LC-MS analysis confirmed complete consumption of 10.3 after 1 h. The reaction mixture was poured into a 50 mL flask and concentrated. The methyl ester was isolated by addition of cold H 2 O to induce precipitation.
  • a reaction vessel was charged with 97 mg (0.26 mmol) 10.3 and dissolved with 10 niL DMF. NaH (31 mg, 0.78 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 15 min. 1 ,4-diiodobutane (43 ⁇ L, 0.33 mmol, 1.25 eq) was then added via syringe and the reaction mixture was allowed to continue stirring at room temperature. HPLC and LC-MS analysis confirmed complete consumption of 10.3 after 4 h during which time addition portions of both NaH and 1 ,4- diiodobutane were added. The reaction mixture was poured into a 50 mL flask and concentrated.
  • the methyl ester was isolated by addition of cold H 2 O to induce precipitation.
  • the resulting solids were then collected by centrifuge and dissolved with 3 mL THF, 1 mL MeOH and 1 mL LiOH (IM, aq.).
  • the reaction mixture was allowed to stir at 50 0 C and monitored by HPLC analysis. When complete, the reaction mixture was neutralized with 0.5 mL HCl (2M, aq.) and concentrated.
  • the crude residue was dissolved with DMF and acidified with TFA. The solution was then filtered and purified by reverse-phase HPLC to afford 20 mg (19%) compound 226 as a white powder.
  • Step 2 Synthesis of compound 227
  • a reaction vessel was charged with 111 mg (0.30 mmol) 11.2 and dissolved with 10 rnL DMF.
  • NaH 36 mg, 0.89 mmol, 3 eq, 60% in mineral oil
  • 1,3-diiodopropane 43 ⁇ L, 0.37 mmol, 1.25 eq
  • HPLC and LC-MS analysis confirmed complete consumption of 11.2 after 70 min. At that time, 1 mL NaOH (2M, aq.) was added. The mixture was heated with stirring to 80 0 C and monitored by HPLC analysis.
  • reaction mixture was neutralized with 1 mL HCl (2M, aq.) and concentrated.
  • the crude residue was dissolved with DMF and acidified with TFA. The solution was then filtered and purified by reverse-phase HPLC to afford 11 mg (9%) 227 as an off-white powder.
  • a reaction vessel was charged with 111 mg (0.30 mmol) 11.2 and dissolved with 10 mL DMF. NaH (36 mg, 0.89 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 15 min.
  • 1 ,4-diiodobutane (49 ⁇ L, 0.37 mmol, 1.25 eq) was then added via syringe and the reaction mixture was allowed to continue stirring at 35 0 C.
  • HPLC and LC-MS analysis confirmed complete consumption of 11.2 after 125 min. At that time, 1 mL NaOH (2M, aq.) was added. The mixture was heated with stirring to 80 0 C and monitored by HPLC analysis.
  • a reaction vessel was charged with 110 mg (0.30 mmol) 11.2 and dissolved with 10 mL DMF. NaH (35 mg, 0.89 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 15 min.
  • 1 ,4-diiodopentane 55 ⁇ L, 0.37 mmol, 1.25 eq was then added via syringe and the reaction mixture was allowed to continue stirring at room temperature.
  • HPLC and LC-MS analysis confirmed complete consumption of 11.2 after 70 min. At that time, 1 mL NaOH (2M, aq.) was added. The mixture was heated with stirring to 80 0 C and monitored by HPLC analysis. When complete, the reaction mixture was concentrated by rotovap.
  • a microwave reaction vessel was charged with 150 mg (0.45 mmol) 10.1, 213 mg (0.58 mmol, 1.3 eq) l-Boc-4-benzyloxyindole-2-boronic acid and 26 mg (0.022 mmol, 0.05 eq) Pd(PPh 3 ) 4 .
  • the reaction vessel was sealed, and subsequently degassed and purged with Argon (Ix).
  • the reaction mixture was then heated by microwave to 80 0 C for 10 min. HPLC and LC-MS analysis confirmed complete consumption of 10.1.
  • the reaction mixture was allowed to cool to room temperature and concentrated by speed-vacuum.
  • a reaction vessel was charged with 107 mg (0.22 mmol) 12.2a and dissolved with 10 mL DMF. NaH (27 mg, 0.67 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 20 min. 1 ,4-diiodobutane (37 ⁇ L, 0.28 mmol, 1.25 eq) was then added via syringe and the reaction mixture was allowed to continue stirring at room temperature. HPLC and LC-MS analysis confirmed complete consumption of 12.2a after 60 min. The reaction mixture was then concentrated and the methyl ester was precipitated with H 2 O.
  • a microwave reaction vessel was charged with 100 mg (0.30 mmol) 10.1, 120 mg (0.33 mmol, 1.3 eq) l-Boc-5-benzyloxyindole-2-boronic acid and 17 mg (0.015 mmol, 0.05 eq) Pd(PPh 3 ) 4 .
  • the reaction vessel was sealed, and subsequently degassed and purged with Argon (Ix).
  • the reaction mixture was then heated by microwave to 70 0 C for 15 min. HPLC and LC-MS analysis confirmed complete consumption of 10.1.
  • reaction vessel was then resealed and heated to by microwave to 160 0 C to cleave the Boc-group.
  • the reaction mixture was then concentrated and the desired methyl ester was precipitated with H 2 O.
  • the solids were collected by centrifuge and dried under vacuum. 12.2b was used without further purification.
  • a reaction vessel was charged with 142 mg (0.30 mmol) 12.2b and dissolved with 10 mL DMF. NaH (36 mg, 0.89 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 20 min. 1 ,4-diiodobutane (49 ⁇ L, 0.37 mmol, 1.25 eq) was then added via syringe and the reaction mixture was allowed to continue stirring at room temperature. HPLC and LC-MS analysis confirmed complete consumption of 12.2b after 80 min. The reaction mixture was then concentrated and the methyl ester was precipitated with H 2 O.
  • a microwave reaction vessel was charged with 150 mg (0.45 mmol) 10.1, 213 mg (0.58 mmol, 1.3 eq) l-Boc-6-benzyloxyindole-2-boronic acid and 26 mg (0.022 mmol, 0.05 eq) Pd(PPh 3 ) 4 .
  • the reaction vessel was sealed, and subsequently degassed and purged with Argon (Ix).
  • the reaction mixture was then heated by microwave to 80 0 C for 10 min.
  • HP LC and LC-MS analysis confirmed complete consumption of 10.1.
  • the reaction mixture was allowed to cool to room temperature and concentrated by speed-vacuum.
  • a reaction vessel was charged with 107 mg (0.22 mmol) 12.2c and dissolved with 10 mL DMF. NaH (27 mg, 0.67 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 20 min. 1 ,4-diiodobutane (37 ⁇ L, 0.28 mmol, 1.25 eq) was then added via syringe and the reaction mixture was allowed to continue stirring at room temperature until HPLC and LC-MS analysis confirmed complete consumption of 12.2c. The reaction mixture was then concentrated and the methyl ester was precipitated with H 2 O.
  • a microwave reaction vessel was charged with 250 mg (0.74 mmol) 10.1, 646 mg (2.22 mmol, 3 eq) l-Boc-5-methoxyindole-2-boronic acid and 43 mg (0.04 mmol, 0.05 eq) Pd(PPh 3 ) 4 .
  • the reaction vessel was sealed, and subsequently degassed and purged with Argon (Ix).
  • the reaction mixture was then heated by microwave to 60 0 C for 40 min.
  • HP LC and LC-MS analysis confirmed complete consumption of 10.1.
  • reaction vessel was then resealed and heated to by microwave to 160 0 C for 10 min to cleave the Boc-group.
  • the reaction mixture was then concentrated and the desired methyl ester was precipitated with H 2 O.
  • the solids were collected by centrifuge and dried under vacuum. Compound 13.2a was used without further purification. MS: 403.2 (M+H + ).
  • Step 2a A reaction flask was charged with 298 mg (0.74 mmol) 13.2a and dissolved with 30 mL DMF. NaH (89 mg, 2.22 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 15 min. 1 ,4-diiodobutane (122 ⁇ L, 0.925 mmol, 1.25 eq) was then added via syringe and the reaction mixture was allowed to continue stirring at room temperature. HPLC and LC-MS analysis confirmed complete consumption of 13.2a after 2.5 h, during which time an additional 0.5 eq of both NaH and 1 ,4-diiodobutane was added.
  • Step 2b One portion from step 2a was dissolved with 3 mL THF, 1 mL MeOH and 1 mL LiOH (IM, aq.). The mixture was then heated with stirring to 80 0 C and monitored by HPLC analysis. When complete, the reaction mixture was neutralized with 0.5 mL HCl (2M, aq.) and concentrated by speed-vacuum. The crude residue was dissolved with DMF and acidified with TFA. The solution was then filtered and purified by reverse- phase HPLC to afford 24 mg (15%) compound 233 as a yellow powder.
  • Step 2a the second portion from step 2a was dissolved with 5 mL CH 2 Cl 2 and 1.8 mL BBr3 (IM, CH 2 Cl 2 ) was carefully added via syringe. The mixture was then allowed to stir at room temperature overnight. The reaction mixture was then poured into 2 mL HCl (2M, aq) and concentrated. The residue was then diluted with EtOAc and extracted twice with NaOH (2M, aq). The combined aqueous phase was acidified with HCl (cone, aq) and extracted with EtOAc. The organic phase was then washed with brine, dried over Na 2 SO 4 , filtered and concentrated. The crude residue was dissolved with DMF and acidified with TFA.
  • Step 1 3-Cyclohexyl-6'-methoxy-lH,l'H-[2,2']biindolyl-6-carboxylic acid methyl ester (13.2b)
  • a microwave reaction vessel was charged with 250 mg (0.74 mmol) 10.1, 646 mg (2.22 mmol, 3 eq) l-Boc-6-methoxyindole-2-boronic acid and 43 mg (0.04 mmol, 0.05 eq) Pd(PPh 3 ) 4 .
  • the reaction vessel was sealed, and subsequently degassed and purged with Argon (Ix).
  • reaction mixture was then heated by microwave to 60 0 C for 40 min. HPLC and LC-MS analysis confirmed complete consumption of 10.1.
  • the reaction vessel was then resealed and heated to by microwave to 160 0 C for 10 min to cleave the Boc-group.
  • the reaction mixture was then concentrated and the desired methyl ester was precipitated with H 2 O. The solids were collected by centrifuge and dried under vacuum. Compound 13.2b was used without further purification. MS: 403.2 (M+H + ).
  • Step 2a A reaction flask was charged with 298 mg (0.74 mmol) 13.2b and dissolved with 30 mL DMF. NaH (89 mg, 2.22 mmol, 3 eq, 60% in mineral oil) was then added and the mixture was allowed to stir at room temperature for 15 min. 1 ,4-diiodobutane (122 ⁇ L, 0.925 mmol, 1.25 eq) was then added via syringe and the reaction mixture was allowed to continue stirring at room temperature. HPLC and LC-MS analysis confirmed complete consumption of 13.2b after 2.5 h, during which time an additional 0.5 eq of both NaH and 1 ,4-diiodobutane was added.
  • Step 2b One portion of step 2a was dissolved with 3 mL THF, 1 mL MeOH and 1 mL LiOH (IM, aq.). The mixture was then heated with stirring to 80 0 C and monitored by HPLC analysis. When complete, the reaction mixture was neutralized with 0.5 mL HCl (2M, aq.) and concentrated by speed-vacuum. The crude residue was dissolved with DMF and acidified with TFA. The solution was then filtered and purified by reverse-phase HPLC to afford 28 mg (17%) compound 235 as an off-white powder.
  • Step 2a the second portion from step 2a was dissolved with 5 mL CH 2 Cl 2 and 1.8 mL BBr3 (IM, CH 2 Cl 2 ) was carefully added via syringe. The mixture was then allowed to stir at room temperature overnight. The reaction mixture was then poured into 2 mL HCl (2M, aq) and concentrated. The residue was then diluted with EtOAc and extracted twice with NaOH (2M, aq). The combined aqueous phase was acidified with HCl (cone, aq) and extracted with EtOAc. The organic phase was then washed with brine, dried over Na 2 SO 4 , filtered and concentrated. The crude residue was dissolved with DMF and acidified with TFA.
  • 6-Bromo-2-(2,4-dimethyl-thiazol-5-yl)-quinoline 14.1 (2.5 g, 7.83 mmol) was dissolved in concentrated H 2 SO 4 (50 rnL) and 90% nitric acid (2 rnL) was added dropwise at 0 0 C. After addition, the mixture was stirred at O 0 C for 10 min and at room temperature for 1 h. The mixture was poured into ice-water (300 mL) and extracted with CH 2 Cl 2 -MeOH (8:1) (100 mL X 5). The combined organic phase was washed with saturated NaHCO 3 (100 mL X 2), water (50 mL X 2) and dried over anhydrous Na 2 SO 4 .
  • Step 6 Synthesis of compound 237 Compound 14.7 (48 mg) was dissolved in MeOH-THF (1 :1) (1.5 niL) and 2 M LiOH (0.5 niL) was added. The mixture was stirred at room temperature for 2.5 h. The mixture was neutralized with 2 N HCl to pH 7. After evaporation of solvent, the residue was purified by reverse phase HPLC to give compound 237 (26 mg, 56%). MS (M+H + ): 537.2.
  • Anti-Hepatitis C Activity Compounds can exhibit anti-hepatitis C activity by inhibiting HCV polymerase, by inhibiting other enzymes needed in the replication cycle, or by other pathways. A number of assays have been published to assess these activities. A general method that assesses the gross increase of HCV virus in culture was disclosed in U.S. Patent No. 5,738,985 to Miles et al. In vitro assays have been reported in Ferrari et al. JnI. ofVir., 73:1649-1654, 1999; Ishii et al, Hepatology, 29: 1227-1235, 1999; Lohmann et al, JnI of Bio. Chem., 274: 10807- 10815, 1999; and Yamashita et al., JnI. of Bio. Chem., 273:15479-15486, 1998.
  • HCV polymerase assay that can be used to evaluate the activity of the of the compounds described herein.
  • Another HCV polymerase assay has been reported by Bartholomeusz, et al., Hepatitis C Virus (HCV) RNA polymerase assay using cloned HCV non-structural proteins; Antiviral Therapy 1996:l(Supp 4) 18-24.
  • HCV Hepatitis C Virus
  • a cell line, ET (Huh-lucubineo-ET) was used for screening of compounds for inhibiting HCV RNA dependent RNA polymerase.
  • the ET cell line was stably transfected with RNA transcripts harboring a l 3 gc>luc-ubi-neo/NS3-37ET; replicon with firefly luciferase-ubiquitin-neomycin phosphotransferase fusion protein and EMCV-IRES driven NS3-5B polyprotein containing the cell culture adaptive mutations (E1202G; T1280I; Kl 846T) (Krieger at al, 2001 and unpublished).
  • the ET cells were grown in DMEM (Dulbeco's Modified Eagle's Medium), supplemented with 10% fetal calf serum, 2 mM Glutamine, Penicillin (100 IU/mL)/Streptomycin (100 ⁇ g/mL), Ix nonessential amino acids, and 250 ⁇ g/mL G418 ("Geneticin"). Reagents are all available through Life Technologies (Bethesda, MD). The cells were plated at 0.5-1.0 xlO 4 cells/well in the 96 well plates and incubated for 24 hrs before adding test compound.
  • DMEM Dynamic Eagle's Medium
  • the compounds were added to the cells to achieve a final concentration of 0.1 nM to 50 ⁇ M and a final DMSO (dimethylsulfoxide) concentration of 0.5%.
  • Luciferase activity was measured 48-72 hours later by adding a lysis buffer and the substrate (Catalog number Glo-lysis buffer E2661 and Bright-Glo luciferase system E2620 Promega, Madison, WI). Cells should not be too confluent during the assay. Percent inhibition of replication data is plotted relative to no compound control. Under the same condition, cytotoxicity of the compounds were determined using cell proliferation reagent, WST-I (Roche, Germany).
  • the compounds of Formula (A) will have an EC50 of equal to or less than 50 ⁇ M when tested according to the assay of Example 2. In other aspects the EC50 is equal to or less than 10 ⁇ M. In still other aspects the EC 50 is equal to or less than 5 ⁇ M.
  • NS5b protein was cloned by PCR from pFKl3gc>luc/NS3- 3'/ET as described by Lohmann, V., et al. (1999) Science 285, 110-113 using the primers shown on page 266 of WO 2005/012288
  • the cloned fragment is missing the C terminus 21 amino acid residues.
  • the cloned fragment was inserted into an IPTG-inducible (isopropyl- ⁇ -D-thiogalactopyranoside) expression plasmid that provides an epitope tag (His)6 at the carboxy terminus of the protein.
  • IPTG-inducible (isopropyl- ⁇ -D-thiogalactopyranoside) expression plasmid that provides an epitope tag (His)6 at the carboxy terminus of the protein.
  • the recombinant enzyme was expressed in XL-I cells and after induction of expression, the protein is purified using affinity chromatography on a nickel-NTA (nitrilotriacetic acid ) column.
  • the polymerase activity was assayed by measuring incorporation of radiolabeled UTP into a RNA product using a biotinylated, heteropolymeric template, which includes a portion of the HCV genome.
  • the assay mixture (50 ⁇ L) contains 10 mM Tris- HCl (pH 7.5), 5 mM MgCl 2 , 0.2 mM EDTA, 10 mM KCl, 1 unit/ ⁇ L RNAsin, 1 mM DTT, 10 ⁇ M each of NTP (nucleoside triphosphate), including [ 3 H]-UTP (uridine triphosphate), and 10 ng/ ⁇ L heteropolymeric template.
  • Test compounds were initially dissolved in 100% DMSO and further diluted in aqueous buffer containing 5% DMSO. Typically, compounds were tested at concentrations between 1 nM and 100 ⁇ M. Reactions were started with addition of enzyme and allowed to continue at 37 0 C for 2 hours. Reactions were quenched with 8 ⁇ L of 100 niM EDTA and reaction mixtures (30 ⁇ L) were transferred to streptavidin- coated scintillation proximity microtiter plates (FlashPlates) and incubated at 4 0 C overnight. Incorporation of radioactivity was determined by scintillation counting.
  • Ingredient tablet mg compound of this invention 400 cornstarch 50 croscarme Hose sodium 25 lactose 120 magnesium stearate 5
  • Ingredient Amount compound of this invention 1.0 g fumaric acid 0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 g granulated sugar 25.O g sorbitol (70% solution)
  • Ingredient Amount compound of this invention 1.0 g fumaric acid 0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 g granulated sugar 25.O g sorbitol (70% solution)
  • Veegum K (Vanderbilt Co.) 1.0 g flavoring 0.035 mL colorings 0.5 mg distilled water q.s. to 100 mL
  • the following ingredients are mixed to form an injectable formulation.
  • Formulation Example 5 Suppository Formulation A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol® H- 15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés et des compositions répondant à la formule (A) et leurs utilisations pour le traitement d'infections virales de Flaviviridae.
EP07799720A 2006-07-20 2007-07-19 Inhibiteurs viraux polycycliques Withdrawn EP2049536A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83252006P 2006-07-20 2006-07-20
PCT/US2007/073898 WO2008011521A2 (fr) 2006-07-20 2007-07-19 Inhibiteurs viraux polycycliques

Publications (1)

Publication Number Publication Date
EP2049536A2 true EP2049536A2 (fr) 2009-04-22

Family

ID=38753551

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07799720A Withdrawn EP2049536A2 (fr) 2006-07-20 2007-07-19 Inhibiteurs viraux polycycliques

Country Status (14)

Country Link
US (1) US20080045498A1 (fr)
EP (1) EP2049536A2 (fr)
JP (1) JP2009544622A (fr)
KR (1) KR20090029827A (fr)
CN (1) CN101528741A (fr)
AR (1) AR062827A1 (fr)
AU (1) AU2007275276A1 (fr)
BR (1) BRPI0714299A2 (fr)
CA (1) CA2657788A1 (fr)
MX (1) MX2009000724A (fr)
PE (1) PE20081113A1 (fr)
RU (1) RU2009105837A (fr)
TW (1) TW200817413A (fr)
WO (1) WO2008011521A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
WO2005049622A1 (fr) * 2003-11-19 2005-06-02 Japan Tobacco Inc. Compose heterocyclique fusionne a cinq branches et utilisation de celui-ci comme inhibiteur de la polymerase du vhc
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
EP2142215B1 (fr) 2007-05-04 2012-03-07 Vertex Pharmceuticals Incorporated Thérapie combinée pour le traitement d'une infection par le vhc
KR20100124848A (ko) * 2008-03-27 2010-11-29 브리스톨-마이어스 스큅 컴퍼니 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제
WO2009143361A1 (fr) * 2008-05-22 2009-11-26 Smithkline Beecham Corporation Composés anti-viraux amido
WO2010096115A1 (fr) 2008-10-29 2010-08-26 Apath, Llc Composés, compositions et procédés pour le contrôle d'infections virales par l'hépatite c
WO2014121416A1 (fr) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2018022897A1 (fr) * 2016-07-27 2018-02-01 Padlock Therapeutics, Inc. Inhibiteurs covalents de pad4

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133402T2 (de) * 1990-04-04 2004-11-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Protease von hepatitis-c-virus
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69434931T2 (de) * 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US5759795A (en) * 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
CA2283379A1 (fr) * 1997-03-05 1998-09-11 Michael G. Katze Nouveaux procedes de criblage permettant l'identification d'agents inhibant de maniere selective la replication du virus de l'hepatite c
CA2312484A1 (fr) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Proteine tronquee du virus ns5b de l'hepatite c et procedes associes d'identification de composes antiviraux
JP2007501189A (ja) * 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
PT1719773E (pt) * 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006046039A2 (fr) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Derives d'indole tetracycliques utilises comme agents antiviraux
US7659263B2 (en) * 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
GB0509326D0 (en) * 2005-05-09 2005-06-15 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0522881D0 (en) * 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008011521A2 *

Also Published As

Publication number Publication date
PE20081113A1 (es) 2008-10-03
AU2007275276A2 (en) 2009-03-19
TW200817413A (en) 2008-04-16
US20080045498A1 (en) 2008-02-21
WO2008011521A2 (fr) 2008-01-24
WO2008011521A3 (fr) 2008-06-26
CA2657788A1 (fr) 2008-01-24
KR20090029827A (ko) 2009-03-23
BRPI0714299A2 (pt) 2013-04-24
CN101528741A (zh) 2009-09-09
JP2009544622A (ja) 2009-12-17
RU2009105837A (ru) 2010-08-27
MX2009000724A (es) 2009-02-04
AR062827A1 (es) 2008-12-10
AU2007275276A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
US20060211698A1 (en) Bicyclic heteroaryl derivatives for treating viruses
WO2008008912A1 (fr) Agents antiviraux
EP2049536A2 (fr) Inhibiteurs viraux polycycliques
JP2010510245A (ja) 抗ウイルス化合物
WO2008064218A2 (fr) Composés amido antiviraux
WO2008154601A1 (fr) Inhibiteurs anti-viraux et procédés d'utilisation
US20070032488A1 (en) 6-Membered aryl and heteroaryl derivatives for treating viruses
US20060293320A1 (en) Heteroaryl derivatives for treating viruses
US20080051384A1 (en) Antiviral agents
US20090197856A1 (en) Antiviral compounds
WO2010081149A1 (fr) Composés antiviraux, compositions et méthodes d'application

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090217

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM CORPORATION

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1130059

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE LLC

17Q First examination report despatched

Effective date: 20100916

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110127

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1130059

Country of ref document: HK